|Description||Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8. Droxinostat shows comparable inhibition of HDAC6 and HDAC8 (IC50 = 2.47 and 1.46 μmol/L, respectively).|
|Synonyms||NS 41080; 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide|
PTACH is a SAHA-based novel inhibitor of histone deacetylase (HDAC). It exerts potent growth inhibition against various human cancer cells, with EC50 values ran...
Mocetinostat is a rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activi...
Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM.
Tubastatin A is selective at all isozymes except HDAC8 and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately...
(-)-Parthenolide is a sesquiterpene lactone which occurs naturally in the plant feverfew(Tanacetum parthenium) and also promotes the ubiquitination of MDM2 and ...
Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8. Droxinostat shows comparable inhibition of HDAC6 and HDAC8 (IC50 = 2.47 and 1.46 μmol/L, respec...
Givinostat hydrochloride monohydrate
Givinostat, also known as ITF2357, is an orally active HDAC inhibitor (IC50= 198 and 157 nM for HDAC1 and HDAC3, respectively), with potential anti-inflammatory...
Givinostat hydrochloride is the hydrochloride salt form of Givinostat. Givinostat, also called as GVS or ITF2357, a potent HDAC inhibitor for Maize HD2 (IC50= 1...
TC-H 106 is a slow, tight-binding inhibitor of class I HDAC, including HDAC 1, 2, and 3 with IC50 values of 150 nM , 760nM, and 370 nM, respectively. It demonst...
Tasquinimod is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease b...
Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects.
UF-010 is a Class I HDAC inhibitor, inhibiting proliferation of a range of cancer cell lines.
GSK3117391, a HDAC inhibitor, was developed by GSK considering its potential effect in the treatment of arthritis and rheumatoid. It was already being terminate...
Belinostat is a novel pan-HDAC inhibitor with IC50 of 27 nM, with activity demonstrated in cisplatin-resistant tumors. It inhibits the growth of tumor cells wit...
BG45 is a class I HDAC inhibitor with IC50 of 289 nM, 2.0 µM, 2.2 µM and >20 µM for HDAC3, HDAC1, HDAC2, and HDAC6 in cell-free assays, respectively.
CUDC-907 is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineo...
ST7612AA1 is a potent Histone deacetylase (HDCA) inhibitor. It showed an in vitro activity in the nanomolar range associated with a remarkable in vivo antitumor...
HDAC-IN-1, an analogue of MC 1568, is a Iia HDACs inhibitor that could probably influence myogenesis and adipogenesis.
CUDC-101 is a multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human e...
RGFP 109 is a histone deacetylase (HDAC) inhibitor that has shown to reverse FXN gene silencing in short-term studies of Friedreich ataxia (FRDA) patient cells.